Your Annual Physical Was 'Normal': The Female Cardiac Tests They Did Not Run

The standard annual physical was not built for the cardiovascular risk profile of a 47-year-old woman in perimenopause. It was built for efficiency, reimbursement constraints, and a clinical literature base that overrepresented men for decades. The default panel captures blood pressure, weight, standard lipid panel, fasting glucose, and sometimes TSH. These catch some things. They miss others that in women, specifically, matter considerably more.

The Mechanism

The mismatch between the standard panel and women’s actual cardiovascular risk profile has a specific physiological basis: women’s cardiac risk is not a smaller-magnitude version of men’s. It follows a different trajectory, operates through different biological mechanisms at key life stages, and responds to different biochemical markers.

In men, LDL cholesterol rises gradually through adulthood and serves as a reasonable proxy for atherogenic burden throughout the preventive window. In women, LDL is relatively stable through the premenopausal years and then rises sharply at the menopause transition, a 10 to 15 percent average increase in LDL-C concurrent with a shift toward smaller, denser LDL particles. This shift happens at exactly the time when the standard panel’s LDL reading becomes least accurate as a measure of atherogenic burden, because smaller denser particles carry less cholesterol per particle: LDL-C stays in the normal range while ApoB, the particle count, rises. The standard panel is measuring the wrong metric at the wrong time.

Insulin resistance follows a parallel trajectory. Women maintain relatively good insulin sensitivity through the reproductive years (progesterone and estrogen both support insulin receptor function), and then experience a measurable deterioration in insulin sensitivity in the perimenopause years even without dietary change. Fasting glucose, the standard screening tool for metabolic risk, does not detect insulin resistance until the pancreas begins to fail at compensation, which occurs years after the vascular damage from hyperinsulinemia and visceral adiposity has already accumulated.

Systemic inflammation in women is amplified by hormonal cycling in the premenopausal years and by cytokine production from visceral adiposity and loss of estrogen’s anti-inflammatory vascular effects after menopause. Women have higher baseline hs-CRP than men, and hs-CRP is a stronger independent predictor of cardiovascular events in women than in men, based on the Reynolds Risk Score validation data from the Women’s Health Study. The standard lipid panel does not measure inflammation. 5 / Solid

The result: a woman in her mid-40s who receives a “normal” annual physical panel may have a substantially elevated atherogenic burden, early insulin resistance, and a significant inflammatory cardiovascular risk load, none of which the standard panel will detect.

What the Evidence Shows

The nine tests most likely to capture what the standard panel misses in women are supported by distinct evidence bases. Each has a specific clinical context where it changes the risk assessment.

ApoB

LDL-cholesterol measures the cholesterol mass inside atherogenic lipoprotein particles. ApoB counts the particles directly, one ApoB protein per particle. In women with insulin resistance, post-menopausal metabolic shifts, or polycystic ovary syndrome, the particles are smaller and denser: low cholesterol content per particle, high particle count. The standard LDL reads as acceptable while the atherogenic burden is substantially higher than it appears. 5 / Solid

The clinical evidence for ApoB superiority over LDL-C is particularly strong in women. A sub-analysis of the INTERHEART study, which enrolled over 15,000 MI cases and matched controls across 52 countries, found that the ApoB-to-ApoA1 ratio was the single strongest lipid predictor of MI risk, outperforming LDL-C, total cholesterol, and HDL-C, and this superiority was pronounced in women. The 2019 ACC/AHA guidelines on cholesterol formally recognized ApoB as a secondary risk marker, recommending its use when LDL-C and risk scores give discordant results.

Target: below 90 mg/dL for most women without established cardiovascular disease; below 70 mg/dL in women with established disease, diabetes, or significant metabolic risk. If LDL-C reads normal and ApoB reads elevated, the ApoB reflects the true atherogenic burden. Ask for it by name.

Lipoprotein(a)

Lp(a) is a genetically determined lipoprotein, an LDL-like particle with an apolipoprotein(a) tail that makes it more thrombogenic, more inflammatory, and more adhesive to arterial walls than standard LDL. Lp(a) does not respond meaningfully to statins or to any dietary intervention. It is genetically fixed from birth. 5 / Solid

The evidence for Lp(a) as an independent cardiovascular risk factor is among the most methodologically robust in preventive cardiology. Mendelian randomization studies, which use genetic polymorphisms associated with naturally higher or lower Lp(a) as instruments for causal inference, confirm that higher Lp(a) causally increases coronary artery disease risk. This is stronger evidence than association alone. The Copenhagen Heart Study, following over 25,000 individuals, found that Lp(a) above 99 nmol/L (approximately 50 mg/dL) carried a 3-fold higher risk of MI and 2.6-fold higher risk of coronary artery disease compared to values below 7 nmol/L, independent of LDL-C, total cholesterol, and all other risk factors.

Approximately 20 percent of women carry Lp(a) values above 50 mg/dL. In women of African descent, prevalence and average levels are higher. Lp(a) only needs to be measured once in a lifetime. If you have never had it measured, ask for it at your next visit.

Fasting Insulin

Fasting glucose detects type 2 diabetes after the pancreatic beta cells have been compensating for years. Fasting insulin detects the compensation itself. A woman with fasting insulin above 10 uIU/mL and completely normal fasting glucose has already developed insulin resistance. That state carries cardiovascular consequences: elevated blood pressure through renal sodium retention and sympathetic activation, visceral fat accumulation that produces inflammatory cytokines, small-dense LDL particle predominance, and direct endothelial damage from hyperinsulinemia. 5 / Solid

The HOMA-IR index (calculated as fasting insulin times fasting glucose divided by 405) quantifies insulin resistance from these two measurements. HOMA-IR above 2.0 identifies meaningful insulin resistance in most populations. Above 2.5, the correlation with visceral adiposity, dyslipidemia, and hypertension is strong.

In the perimenopause years, insulin sensitivity decreases measurably even without dietary change. The fasting insulin detects this deterioration when it is early and addressable. A1c and fasting glucose will not reflect the change until years later. The decade between perimenopause-onset insulin resistance and clinically detectable glucose impairment is the window where intervention has the greatest return.

High-Sensitivity CRP

Standard CRP detects acute inflammation at clinically elevated concentrations. High-sensitivity CRP measures the same protein at the low-grade concentrations that reflect chronic vascular inflammation. The predictive evidence for hs-CRP specifically in women is particularly strong.

The JUPITER trial enrolled 17,802 apparently healthy adults with LDL-C below 130 mg/dL and hs-CRP at or above 2.0 mg/L. Rosuvastatin 20 mg reduced MI, stroke, and cardiovascular death by 44 percent overall, with a significant interaction showing women with elevated hs-CRP derived substantial cardiovascular risk reduction even in the absence of elevated LDL-C. The trial was designed in part around the hypothesis, derived from the Women’s Health Study data, that hs-CRP predicts cardiovascular risk independently of LDL in women. It confirmed that hypothesis and provided the evidence basis for treating women with elevated hs-CRP and normal LDL with statins. 5 / Solid

Women have higher baseline hs-CRP than men, partly due to hormonal cycling and partly due to adipose tissue cytokine production. The threshold where hs-CRP signals elevated cardiovascular risk independent of lipid levels is above 2.0 mg/L. Below 1.0 mg/L is low risk. Between 1.0 and 2.0 is intermediate. Above 2.0 mg/L in a woman with a normal standard lipid panel identifies a patient who needs a different conversation than her lipid panel alone would generate.

Ferritin

Ferritin is the body’s stored iron measurement. Low ferritin, even in the complete absence of anemia, causes fatigue, reduced exercise tolerance, palpitations, elevated resting heart rate, and dyspnea on exertion. These are also the presenting symptoms of cardiac disease in women, and the differential matters substantially. 5 / Solid

In women of reproductive age, iron deficiency without anemia is the most common micronutrient deficiency, affecting approximately 12 to 16 percent of women in the United States. Ferritin can be significantly depressed, below 30 ng/mL, while hemoglobin remains entirely normal. The symptoms are real and often severe. A woman presenting to cardiology with fatigue, palpitations, and reduced exercise capacity who has ferritin of 11 ng/mL has a treatable cause of her symptoms that is frequently missed because hemoglobin is checked rather than ferritin.

The laboratory interaction with A1c is less widely known but clinically important: iron deficiency shortens red blood cell lifespan, causing A1c to underestimate the actual average glucose over the preceding three months. A woman with ferritin of 8 ng/mL and A1c of 5.4 percent may have a true metabolic glucose picture that A1c cannot accurately reflect. The iron deficiency is masking early glycemic impairment.

24-Hour Ambulatory Blood Pressure

A single blood pressure reading in a clinical office captures one moment in a setting that induces anxiety in a substantial proportion of patients. It cannot detect nocturnal blood pressure dipping, morning surge hypertension, or the difference between white-coat hypertension and true sustained hypertension. These distinctions carry significant clinical implications.

The Ohasama study, following 1,542 adults for a mean of 9 years, found that nighttime blood pressure was a stronger predictor of cardiovascular mortality than daytime blood pressure, and that non-dipping status independently predicted events after adjustment for average 24-hour pressure. The Dublin Outcome Study confirmed that ambulatory blood pressure, specifically nocturnal readings, outperformed office readings in predicting cardiovascular events in a European cohort of over 5,000 patients.

In women with borderline daytime readings, reported nocturnal symptoms or palpitations, suspected sleep apnea, or hot flash-disrupted sleep, ambulatory blood pressure monitoring provides information that cannot be obtained from office readings and that directly changes management decisions.

Coronary Artery Calcium Score

The CAC score is not a blood test. It is a 12-minute, low-radiation CT scan that directly images calcium deposits in the coronary arteries, providing anatomical evidence of subclinical atherosclerosis. Its clinical value is in reclassification: the CAC score changes the risk category for a substantial proportion of patients in the intermediate-risk range and can support or defer preventive interventions with a level of precision that calculator-based risk scores cannot match. 5 / Solid

For women specifically, the CAC score is arguably more important than for men because women are systematically excluded from the intermediate-risk category by standard calculators, which were derived from cohorts with poor female representation. A woman whose 10-year Pooled Cohort Equation risk is 7.5 percent may have a CAC of zero, genuinely low risk, or a CAC of 250, dramatically higher risk than the calculator suggests. These two patients require different conversations and different treatment thresholds.

Any CAC above zero in a woman under 55 is a clinically significant finding that changes the preventive conversation. A CAC of zero in a woman with multiple risk factors lowers her calculated event risk and may support deferring therapies whose benefit-risk balance is otherwise ambiguous. The scan typically costs $100 to $150 out of pocket at a radiology center when not covered by insurance for primary prevention.

DHEA-S

DHEA-S is the most abundant circulating sex-steroid precursor, produced primarily by the adrenal cortex. It declines substantially after age 40, approximately 10 percent per decade. Low DHEA-S correlates with fatigue, reduced muscle mass, and insulin resistance in cross-sectional and longitudinal studies. More relevantly for cardiovascular risk assessment: DHEA-S correlates inversely with metabolic syndrome components and with markers of cardiovascular risk, though the relationship is associative rather than causal and the evidence for DHEA-S supplementation improving cardiovascular outcomes is not established.

The clinical value of measuring DHEA-S in women 40 to 55 is primarily differential: fatigue, reduced exercise tolerance, and mood change in this age group may reflect low DHEA-S rather than, or in addition to, low thyroid, low iron, or cardiac pathology. Identifying the hormonal contribution to symptoms allows it to be addressed directly.

Menopause-Stage Hormone Panel in Women 40 to 55

FSH and estradiol provide clinical context for interpreting the cardiovascular risk changes that accompany the menopause transition. FSH above 40 IU/L with low estradiol indicates late perimenopause or postmenopause. AMH (Anti-Mullerian Hormone) can identify women entering the menopausal transition earlier than expected, which has implications for the timing of the LDL surge, insulin resistance onset, and vascular aging acceleration that accompany estrogen withdrawal.

These values do not directly predict cardiovascular events, but they contextualize the metabolic and vascular changes that follow estrogen decline and establish a baseline for conversations about the timing and appropriateness of menopausal hormone therapy, cardiovascular risk escalation, and bone density assessment.

What to Do This Week

1. At your next visit, request: “Can we add ApoB, fasting insulin, hs-CRP, and Lp(a) to my labs this year?” These four tests are available at any commercial laboratory. They require no special preparation beyond the fasting state already required for the standard lipid panel.

2. Ask specifically: “Has my Lp(a) ever been measured?” If the answer is no, request it now. It requires measurement only once in a lifetime and remains useful for the duration of clinical management.

3. Ask: “Is a coronary artery calcium score appropriate for me at this point?” For women between 40 and 60 whose risk category is genuinely intermediate on standard calculators, this is the single most decision-informing test available. Ask by name.

4. If you have fatigue, palpitations, or reduced exercise tolerance, ask for a ferritin measurement specifically, not just hemoglobin or CBC. Iron deficiency without anemia will not appear on a CBC. It requires ferritin.

5. If requests are declined as not clinically indicated, ApoB, Lp(a), hs-CRP, and fasting insulin are available for direct ordering through LabCorp Patient Direct, Quest Direct, or Function Health without a physician order. The tests exist. The data they generate are clinically actionable.

The annual physical is a limited encounter. The default panel it generates reflects the constraints of that encounter. What it does not include is a judgment that those tests are unnecessary. The additional tests described here are supported by evidence, accessible, and capable of changing the clinical picture substantially for women in the perimenopause window. They require someone to ask for them.

Related Reading

For the specific lab panel cardiologists recommend at 45: The Women’s Cardiac Screening Lab Panel.

For what ApoB specifically shows that LDL misses: the Five Numbers module covers ApoB, Lp(a), hs-CRP, fasting insulin, and CAC in sequence.

For why the standard panel was built around male physiology: Why Women’s Heart Disease Gets Dismissed.